Verimatrix Virtual Summit to Offer the Industry’s Latest Insights into Secure Video Delivery and Mobile Application Protection July 8-9
30.6.2020 18:45:00 EEST | Business Wire | Press release
Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced its second virtual event this year designed to showcase how the global expansion of video, applications and connected devices has multiplied today’s attack surfaces. The Verimatrix Summer Summit consists of webcasts and private meetings taking place Wednesday, July 8, and Thursday, July 9, 2020.
“Now more than ever, organizations need to provide their customers with compelling experiences – but those experiences must be protected,” said Asaf Ashkenazi, COO of Verimatrix. “The Verimatrix Summer Summit will showcase why security matters more than ever -- and why in today’s modern connected world, security should be intuitive, user-friendly, and fast."
To kick off the Summit, Verimatrix Chairman and CEO Amedeo D’Angelo will underscore the importance of reliable and trustworthy security in the high-growth areas of video content, mobile applications and connected devices.
Verimatrix Virtual Summit Experience
Trusted Security: What it Means to Be a Trusted Security Partner
Wednesday, July 8, 6:30am PT / 1:30pm GMT
Amedeo D’Angelo, Chairman and CEO of Verimatrix, will explore what it means to be a trusted security partner, how the global expansion of video, applications and connected devices has multiplied today’s attack surfaces, and why the future of scalable, cost-effective SaaS security in the cloud is so exciting.
Every Second Counts: Building Better Sports Fan Experiences Through Secure Mobile Apps and Connected Game Play
Wednesday, July 8, 7:00am PT / 2:00pm GMT
Produced and moderated by SportsPro, this webinar will showcase how today’s technological change is forever altering fan perceptions and demands for the sporting experience. Franchises who provide trusted gameday ecosystems will win over the hearts, minds and pocketbooks of fans – while preserving valuable revenue streams. Panelists include Leanne Johnson, VP of Digital for the Milwaukee Bucks and Lucas von Cranach, CEO and Founder of Onefootball. Eoin Connolly, Editor-At-Large for SportsPro, will moderate.
Cloud Speed Ahead: Unlocking New Opportunities with Secure Content Distribution
Wednesday, July 8, 8:00am PT / 3:00pm GMT
Produced by Omdia, this webinar will explore how content providers are efficiently setting up new distribution channels around the world by maximizing novel OTT direct-to-consumer strategies without breaking the bank. Allen Tatara, Sr. Manager, Webinar Events at Omdia will moderate. Panelists will include Geoff Stedman, Enterprise Media Strategist at AWS Elemental, Asaf Askenazi, Chief Operating Officer at Verimatrix and Merrick Kingston, Associate Director at Omdia.
Apps Under Siege: Understanding Today’s Threats to Web/Mobile Applications and How to Defend Your IP While Safeguarding Customers
Wednesday, July 8, 11:30am PT / 6:30pm GMT
Experts from Jscrambler and Verimatrix will discuss how the lack of application protection is a giant blind spot and source of risk for many companies. Whether they want to acknowledge it or not, virtually every company today is in the app business. This webinar will reveal how to protect apps from harm without degrading the user experience. Lu Bolden, Chief Revenue Officer at Verimatrix will moderate. Panelist will include Pedro Fortuna, Co-Founder & CTO at Jscrambler and Neal Michie, Director Product Management at Verimatrix.
Defend and Protect: How Cybercriminals Are Hacking Healthcare Workflows & How to Stop Them
Thursday, July 9, 8:00am PT / 3:00pm GMT
Moderated by Adam Turinas, this panel session will explore how cybercriminals can cripple healthcare workflows. It will uncover how tele-health platforms, apps and devices can be hacked relatively easily, share examples of breaches and review the latest security techniques. The results of a security effectiveness test of the world’s top 20 healthcare apps will be shared during the session. The webinar will be moderated by Adam Turinas, CEO & Founder of HealthLaunchpad. Panelists include John Ulett, CIO of CentraState Healthcare System, John Hendricks, CTO of Huntzinger Management Group, Brian Lawrence, Director Solution Engineering at NowSecure and Asaf Ashkenazi, Chief Operating Officer at Verimatrix.
Churning It Around: How to Identify and Retain At-Risk Video and Internet Service Subscribers Using Data Stories
Thursday, July 9, 9:00am PT / 4:00pm GMT
This panel will explore how security vendors and systems integrators are working with operators to utilize the latest data harvesting & analytics tools to surface subscriber profitability stories. This can lead to actionable insights powerful enough to boost consumption rates, reduce churn and increase ARPU – all of which are especially critical in a climate of tight pocketbooks caused by COVID-19. Moderated by Sebastian Braun, Director Product Management at Verimatrix, this panel will feature Luc Bleylevens, Senior Product Director, Subscriber Retention Management at Cleeng, Daragh O Brien, CEO & Managing Director of Castlebridge and Derek Harrar, CEO of Zodiac.
Adapt or Die: The Content Distribution Business Model in Flux
Thursday, July 9, 11:30am PT / 6:30pm GMT
Speakers from Xperi (TiVo) and 3Vision come together for this insightful session on the impact of COVID-19 on the traditional Hollywood business and their audiences. Topics to be explored include what’s changing within the content distribution business model and why, the shifting power of content producers, trends in security technologies and integration methods and more. Moderated by Lu Bolden, Chief Revenue Officer at Verimatrix, this webinar will feature Nic Wilson, Head of Customer Success at TiVo and Jack Davison, EVP of 3Vision.
To learn more about the Verimatrix Summer Summit, or register to attend any of the sessions go to www.summit.verimatrix.com.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. To learn more, visit www.verimatrix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005500/en/
Contact information
Investor and media
Investor Relations
Richard Vacher Detournière
General Manager & Chief Financial Officer
+33 (0)4 42 905 905
finance@verimatrix.com
Contact Media
Kelly Foster
+1 619 224 1261
kfoster@verimatrix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom